Biocryst Pharmaceuticals vs Ionis Pharmaceuticals
Biocryst Pharmaceuticals and Ionis Pharmaceuticals are similar in size: $875m and $944m of revenue in their latest fiscal years. Biocryst Pharmaceuticals grew faster (94.1% against 33.8%). Biocryst Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 30.2% against -40.4%.
| Latest fiscal year | Biocryst PharmaceuticalsBCRX, 2025 | Ionis PharmaceuticalsIONS, 2025 |
|---|---|---|
| Revenue | $875m | $944m |
| Revenue growth | 94.1% | 33.8% |
| Net income | $264m | −$381m |
| Operating margin | 39.0% | -40.4% |
| Net margin | 30.2% | -40.4% |
| Return on equity | — | -70.8% |
| Free cash flow | $345m | −$320m |
| Cash | $89.7m | $372m |
| Total debt | $0 | $1.81bn |
| Debt to equity | — | 370.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 435 | 1,402 |
| Market value | $2.19bn | $6.75bn |
| Price vs our value range | Below our value range | — |
| Moat score | 46 (Moderate) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 10 sales | 2 buys, 116 sales |